Ketorol (Ketorolac Trometamol)

Ketorolac trometamol works by non‑selectively inhibiting the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes. This reduces the production of prostaglandins, which are key mediators of inflammation, pain, and fever, thereby providing analgesic and anti‑inflammatory effects.

The specific dose and dosing interval of Ketorol are determined by the prescribing clinician based on the patient’s condition, weight, renal function, and the route of administration. Only a qualified health professional should set the regimen.

Ketorol is generally contraindicated in the third trimester of pregnancy because of the risk of fetal renal impairment and premature closure of the ductus arteriosus. Limited data exist for use during lactation, so it should only be used if the potential benefit outweighs the risk and under medical advice.

To order Ketorol, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

Ketorol is a potent NSAID with a relatively rapid onset of analgesia, making it useful for short‑term, high‑intensity pain. Compared with ibuprofen or naproxen, it provides stronger pain relief but carries a higher risk of gastrointestinal and renal adverse effects, so its use is limited to brief treatment periods.

Ketorol for injection should be stored at 2‑8 °C in a refrigerator. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product reaches room temperature for a short period, it may be used, but it should be returned to refrigeration promptly.

Ketorol is supplied as an injectable solution and is administered either intramuscularly or intravenously by a qualified health professional. The injection site and rate of administration are chosen based on the clinical situation and the patient’s overall health status.

The most serious risks include gastrointestinal bleeding or ulceration, acute renal failure, severe allergic reactions such as anaphylaxis, and cardiovascular events like myocardial infarction or stroke. Patients should be monitored closely for signs of bleeding, reduced urine output, or allergic symptoms.

Ketorol should be avoided in patients with known hypersensitivity to ketorolac or other NSAIDs, those with active peptic ulcer disease, severe renal impairment, uncontrolled hypertension, recent coronary artery bypass graft surgery, and in the third trimester of pregnancy. Caution is also advised for the elderly and for patients on anticoagulants.